Akèy › Kansè tete negatif triple › Main
Etid klinik pou Kansè tete negatif triple nan Main
3 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan Main.
Tèks ofisyèl etid la (Anglè)
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- New England Cancer Specialists ( Site 0051), Westbrook
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06966700Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- New England Cancer Specialists, Scarborough
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT05633654Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- Eastern Maine Medical Center, Brewer
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 29, 2026 · NCT04468061Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.